Related Experiment Video
Updated: Aug 20, 2026
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
[Animal models for sepsis]
1Department of Emergency and Critical Care Medicine, Tohoku University, Graduate School of Medicine.
Abstract:
Despite promising preclinical evidence, dozens of new anti-sepsis agents have failed to demonstrate clinical efficacy. One of the reasons may be that the preclinical trials were conducted using animal models that did not adequately reflect clinical realities. Various kinds of experiments utilized for the development of new agents were carried where bolus or short term continuous infusions of large doses of bacteria or endotoxin were administered intravenously. For the preclinical testing of agents, (1) i.v. bacteria and endotoxin models in which the total challenge dose of adequate bacteria or endotoxin is reduced and/ or the length of administration time is increased, and (2) peritonitis models, e.g., cecal ligation and puncture and peritoneal implantation of bacteria or endotoxin, will become reasonable choices.
Insights
Many anti-sepsis treatments fail in clinical trials because preclinical models don't mimic real-world sepsis. Revised animal models, using reduced doses or longer administration times for bacteria and endotoxin, are proposed for better testing.
Area of Science:
- Sepsis research
- Preclinical drug development
- Animal modeling
Context:
- Numerous sepsis drug candidates fail in clinical trials despite promising preclinical data.
- Existing preclinical models often use unrealistic high-dose, short-term bacterial or endotoxin challenges.
- These models may not accurately represent the complex pathophysiology of human sepsis.
Purpose:
- To identify more clinically relevant preclinical models for testing anti-sepsis agents.
- To address the high failure rate of sepsis therapeutics in human trials.
- To improve the predictive value of animal studies for sepsis drug development.
Summary:
- Preclinical sepsis models frequently involve intravenous administration of large bacterial or endotoxin doses over short periods.
- This approach may not accurately recapitulate the gradual onset and progression of sepsis in patients.
- Revised models are suggested, including intravenous challenges with reduced doses or extended administration times, and peritonitis models like cecal ligation and puncture.
Impact:
- More effective anti-sepsis agents may be identified through improved preclinical testing.
- This could lead to better treatment outcomes for patients suffering from sepsis.
- Enhanced translational success from preclinical research to clinical application in sepsis therapy.
